Join
Live feed
·
PRReleasevia Quantisnow
Abpro Holdings Inc logo

Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers

ByQuantisnow·Wall Street's wire, on your screen.
ABP· Abpro Holdings Inc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ABP (Abpro Holdings Inc) and more on Quantisnow.